Stock ALKS ALKERMES PLC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Alkermes plc

Equities

ALKS

IE00B56GVS15

Real-time Estimate Cboe BZX
Other stock markets
 18:34:20 02/05/2024 BST 		5-day change 1st Jan Change
23.62 USD -1.62% Intraday chart for Alkermes plc -3.42% -14.91%
05:29pm UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating MT
05-01 Alkermes's Q1 Earnings, Revenue Grow But Miss Street View MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ALKERMES PLC Stock Alkermes plc
-14.91% 4.06B
B
MODERNA, INC. Stock Moderna, Inc.
+23.81% 42.68B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.31% 42.4B
B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
A
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.89% 24.94B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.98% 18.96B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.22% 12.3B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.78% 11.95B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-1.47% 11.55B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ALKS Stock
  4. Ratings Alkermes plc